Intervention not reported
Participants with a serious adverse event · adults with moderate or severe acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Deaths · adults with moderate or severe acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
At least 50% of maximum pain relief over 4 to 6 hours · adults with moderate or severe acute postoperative pain
The intervention leads to higher at least 50% of maximum pain relief over 4 to 6 hours (high certainty).
1 finding from 1 review
RR 5.6 [4, 7.8]
Studies not reported
High
Intervention not reported
Participants with at least 1 adverse event · adults with moderate or severe acute postoperative pain
The intervention showed no clear difference in participants with at least 1 adverse event (moderate certainty).
1 finding from 1 review
RR 0.93 [0.74, 1.2]
Studies not reported
Moderate
Intervention not reported
Participants with a serious adverse event · adults with moderate or severe acute postoperative pain
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Deaths · adults with moderate or severe acute postoperative pain
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Failure to induce clinical remission at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce clinical remission compared with placebo (high certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower failure to induce clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce endoscopic remission compared with placebo (high certainty).
1 finding from 1 review
Clinical relapse · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower clinical relapse compared with placebo (moderate certainty).
1 finding from 1 review
Endoscopic relapse · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower endoscopic relapse compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Pain‐free response at 2 h · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Intervention not reported
Headache relief at 2 h · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Intervention not reported
Headache relief at 1 h · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Intervention not reported
Sustained pain‐free during the 24 h post dose · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
Sustained headache relief during the 24 h post dose · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Intervention not reported
At least one AE · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Intervention not reported
Serious AE* · adults with migraine headache ‐ moderate or severe pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate